July 31 (Reuters) - Moderna ( MRNA ) beat Wall Street
estimates for second-quarter revenue on Friday benefiting from
better-than-expected sales of its COVID-19 vaccine, as the
company gears up for the potential launch of its flu shot.
The company reported second-quarter revenue of $145 million,
compared with analysts' average estimate of $103 million,
according to LSEG data.